Phase 2 N=7 Efficacy and Safety Study of Velaglucerase Alfa in Children and Adolescents With Type 3 Gaucher Disease
Gaucher Disease, Type 3
Primary: Change From Baseline to 12 Months (Week 53) in Hemoglobin Concentration — 2.15 g/dL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=77 A Personalized Dashboard to Educate Veterans at Risk of Stroke
Cardiovascular Disease · Stroke
Primary: Change in Percentage of Participants Who Initiate Conversation With Primary Care Provider About Vascular Risk — 11.1; -21.4 percentage of patients
Phase 3 N=50 Effects of Creatine Supplementation on Muscle Mass and Function Among Older Women Subjected to Resistance Training
Muscle Weakness
Primary: Rectus Femoris Cross Sectional Height — 17.5; 17.6 cm
Phase 3 N=414 Omarigliptin (MK-3102) Clinical Trial - Placebo- and Sitagliptin-Controlled Monotherapy Study in Japanese Patients With Type 2 Diabetes Mellitus (MK-3102-020)
Type 2 Diabetes Mellitus
Primary: Change From Baseline for Hemoglobin A1c (HbA1c) at Week 24 — -0.66; -0.65; 0.13 Percent HbA1c — p=<0.001
N/A N=465 An Observational Study of Tarceva (Erlotinib) in Elderly Patients With Advanced Non-Small Cell Lung Cancer
Non-Squamous Non-Small Cell Lung Cancer
Primary: Percentage of Participants Who Were Alive 1 Year After Start of Treatment — 30.6; 26.6; 29.8; 37.2 percentage of participants
Phase 1 N=19 Trial Evaluating OPC-34712 in Subjects With Normal Renal Function and Renally Impaired Subjects
Schizophrenia · Psychiatric Disorders
Primary: Unbound Area Under the Concentration (AUC) Time Curve Calculated to the Last Observable Concentration Brexpiprazole (AUCt,u). — 8.17; 13.3 nanograms*hours/mL (ng*h/mL)
Phase 1 N=218 Trial to Evaluate the Effects of OPC-34712 on QT/QTc in Subjects With Schizophrenia or Schizoaffective Disorder
Schizophrenia · Schizoaffective Disorder
Primary: Time-matched QTcI Change From Baseline (Day -1) Corrected for Placebo on Day 11 Following Brexpiprazole Treatment. — 9.2; -0.2; 2.6; 9.4 msec
Phase 2 N=40 Ph II SAHA and Bevacizumab for Recurrent Malignant Glioma Patients
Recurrent Glioblastoma Multiforme · Malignant Glioma · Adult Brain Tumor
Primary: Six-month Progression-free Survival (PFS6) — 30 percentage of participants
Phase 2 N=685 A Dose-Range Finding Study in Participants With Type 2 Diabetes (MK-3102-006)
Type 2 Diabetes Mellitus
Primary: Change From Baseline in Plasma A1C Levels at Week 12 — -0.14; -0.36; -0.35; -0.53 Percent — p=<0.001
Phase 3 N=636 Study of the Effectiveness of Three Different Doses of OPC-34712 in the Treatment of Adults With Acute Schizophrenia
Acute Schizophrenia
Primary: Mean Change From Baseline to Week 6 Positive and Negative Syndrome Scale (PANSS) Total Score. — -19.65; -20.73; -14.90; -12.01 Units on a scale — p=<0.0001
Phase 2 N=66 Determining the Feasibility of Spinal Cord Neuromodulation for the Treatment of Chronic Heart Failure
Heart Failure
Primary: Evaluate the Reduction in Left-ventricular End Systolic Volume Index (LVESVi) After 6 Months of Spinal Cord Stimulation (SCS) Therapy in the Treatment Arm Compared to…
Phase 2 N=244 Multicenter, Open-label, Safety and Tolerability Study
Schizophrenia
Primary: Number of Participants With Adverse Events (AEs) During First 6 Weeks. — 79; 19; 7; 78 Participants
Phase 2 N=50 A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (TRIGGER)
Non-Squamous Non-Small Cell Lung Cancer
Primary: Percentage of Participants With Disease Progression or Death at 12 Months After Baseline — 42 percentage of participants
Phase 3 N=1,365 Bacterial Vaginosis Home Screening to Prevent STDs
Bacterial Vaginosis
Primary: One-year Incidence of Chlamydial and Gonococcal Infections in Women Who Receive Screening (Every 2 Months) and Treatment for Asymptomatic Bacterial Vaginosis as Compared…
Phase 3 N=1,703 Chloroquine for Malaria in Pregnancy
Malaria
Primary: Incidence of Placental Malaria Infection Based on Histology — 11.58; 15.42; 15.42 percentage of pregnancies — p=0.2441